The Red Light Therapy Scandal; Methylene Blue, Urolithin A & the Aging Discovery That Changes Everything

Every month there's an avalanche of new research — but very little of it actually changes how we think about health.

In this episode of The Energy Code, Dr. Mike Belkowski breaks down the most important mitochondrial research published over the last month and separates genuine scientific progress from marketing hype.

You'll learn why independent testing revealed that some commercial red light therapy devices don't emit the wavelengths they claim, why that matters far more than advertised power output, and what consumers should actually be looking for.

Dr. Mike also explores the latest mechanistic research on methylene blue, the expanding clinical evidence behind Urolithin A, and a fascinating new body of mitochondrial science suggesting that dysfunctional mitochondria may actively drive inflammation and aging through cellular signaling — not simply by producing less energy.

If the recent science is pointing in one direction, it's this:

Mitochondrial quality may be one of the most important upstream regulators of health, resilience, and longevity.

Whether you're interested in red light therapy, methylene blue, Urolithin A, or simply understanding where longevity science is headed next, this episode provides an evidence-based review of the month's biggest developments.

(Educational content only, not medical advice.)

-

Key Quotes From Dr. Mike:

"Wavelength is the identity of the treatment... Power output can often be compensated for. Wavelength cannot."

"Consumers should care whether companies are willing to have their products independently tested."